• Tags: myopia
Myopia Focus launches customizable patient education tools for ECP websites
Business

Myopia Focus launches customizable patient education tools for ECP websites

UK-based initiative’s Tool Creator enables clinical practice to create and embed interactive education tools directly into their digital interfaces.
New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression
Pipeline

New SightGlass 24-month data shows DOT lenses significantly slow pediatric myopia progression

Unveiled at ARVO 2026, DOT lenses saved more than 1 D of myopic progression on average after 2 years among 6-to-10-year-old wearers.
Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression
Research

Breakthrough trial finds MiYOSMART iQ spectacle lenses halt childhood myopia progression

Latest 12-month data details highest myopia-control efficacy results reported to date in myopes as young as age 4 wearing HOYA’s D.I.M.S. technology.
Leadership watch: Updates from Nanoscope, Topcon, Tenpoint, and TheiaLife
Business

Leadership watch: Updates from Nanoscope, Topcon, Tenpoint, and TheiaLife

Leadership changes are underway in the eyecare space—and we’ve got the latest.
Researchers question safety of red light among pediatric myopes
Research

Researchers question safety of red light among pediatric myopes

Laboratory analysis suggests some devices may exceed established retinal safety limits during recommended treatment times.
Study links poor diet with increased pediatric myopia
Research

Study links poor diet with increased pediatric myopia

Cross-sectional study finds diets heavy in processed and sugar foods increase risk, while those rich in nuts, legumes, and whole grains appear protective.
Sydnexis's low-dose atropine shows strong phase 3 efficacy for pediatric myopia
Pipeline

Sydnexis's low-dose atropine shows strong phase 3 efficacy for pediatric myopia

Recent 3-year data from the STAR trial meets primary and secondary endpoints for SYD-101, including the greatest treatment benefits among younger myopes.
Registration opens for Eyes On Myopia 2026
Events

Registration opens for Eyes On Myopia 2026

Virtual event kicks off May 9 in partnership with Woo University, offering up to 5 hours of COPE-accredited CE credits.
High myopes face increased PCO risk with hydrophilic IOLs
Research

High myopes face increased PCO risk with hydrophilic IOLs

Study finds hydrophobic IOLs reduced the risk of PCO in highly myopic eyes by 41%.
Lutein shows potential as myopia management supplement
Research

Lutein shows potential as myopia management supplement

Preliminary RCT data highlights preservation of choroidal thickness in children taking lutein supplements.
HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia
Research

HOYA reports 6-month data on MiYOSMART iQ spectacle lenses for pediatric myopia

Interim results find advanced lens and D.I.M.S. triple enhanced design tech to be twice as effective in controlling axial elongation and disease progression.
Conflicting evidence surrounds astigmatism's role in myopia
Research

Conflicting evidence surrounds astigmatism's role in myopia

Study highlights need for further investigation into the impact of astigmatism on myopia onset and progression.
Euclid Vision launches new SiHy daily disposable lens for myopia
Products

Euclid Vision launches new SiHy daily disposable lens for myopia

The Be Free Day soft lens for pediatric myopes features BHVI's proprietary dual action, multistep optical design technology.
Research finds limited benefits of outdoor exposure for premyopic children
Research

Research finds limited benefits of outdoor exposure for premyopic children

Protective effect of time outdoors observed in hyperopes and premyopic children after spending >120 minutes/day outside.
Essilor Stellest 2.0 lenses demonstrate superior efficacy in slowing myopia progression
Research

Essilor Stellest 2.0 lenses demonstrate superior efficacy in slowing myopia progression

Upgraded FDA-authorized spectacle lenses for pediatric myopia control found to slow axial elongation more effectively after 1 year with advanced technology.
Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia
Pipeline

Sydnexis reports phase 3 topline data on SYD-101 eye drop for pediatric myopia

The STAR study met both primary and secondary endpoints for low-dose atropine formulation—just days after the FDA’s NDA rejection.
Myopia may delay DR development and progression
Research

Myopia may delay DR development and progression

Study used Mendelian randomization to identify a causal relationship between myopia and diabetic retinopathy.
FDA rejects Sydnexis’ NDA for low-dose atropine drop
Pipeline

FDA rejects Sydnexis’ NDA for low-dose atropine drop

SYD-101 still has the potential to become the first pharmaceutical option for progressive myopia for patients aged 3 to 14.
Myopia Profile debuts AI virtual assistant for disease management
Products

Myopia Profile debuts AI virtual assistant for disease management

Ask Kate is trained to deliver real-time, evidence-based responses to help ECPs stay updated on the latest clinical and scientific research.
GMAC launches free myopia awareness toolkit for ECPs
Events

GMAC launches free myopia awareness toolkit for ECPs

Downloadable resources include take-home brochures, social media graphics, and more to raise awareness and education of pediatric disease progression.